High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients

A reappraisal of prognostic factors

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Treatment included high-dose carmustine, etoposide, cytarabine and melphalan in 84 patients and high-dose idarubicin and melphalan in 13 patients with subsequent peripheral hemopoietic stem cells transplant. Outcomes were evaluated in terms of progression-free survival (PFS) and overall survival (OS). In order to identify prognostic factors for outcome, a multivariate analysis for age, sex, disease status (refractory/relapsed), disease stage, B symptoms, presence of extranodal involvement, bulky disease, elevated lactate dehydrogenase, number of previous chemotherapy lines, remission status before transplant, 18F-fluoro-deoxy-d-glucose positron emission tomography (18FDG-PET) status before and after transplant was done. A clinical response was achieved in 91% of patients, with complete remissions in 76/97 patients. With a median follow-up of 45months (range 1-164months), 5-year PFS and OS were 64% and 71%, respectively. Remission status after induction therapy, 18F-fluoro-deoxy-d-glucose positron emission tomography status before and after transplant were the most important prognostic factors for PFS and OS in univariate or multivariate analyses. HDCT is able to induce a high remission rate and a prolonged PFS in more than 50% of the patients with refractory and relapsed HL.

Original languageEnglish
Pages (from-to)34-40
Number of pages7
JournalHematological Oncology
Volume31
Issue number1
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Hodgkin Disease
Drug Therapy
Disease-Free Survival
Transplants
Melphalan
Positron-Emission Tomography
Survival
Multivariate Analysis
Idarubicin
Glucose
Carmustine
Cytarabine
Etoposide
L-Lactate Dehydrogenase
Therapeutics

Keywords

  • Autologous transplant
  • High-dose chemotherapy
  • Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{a2c532c1f74449f8b67f157118e7cda0,
title = "High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: A reappraisal of prognostic factors",
abstract = "High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Treatment included high-dose carmustine, etoposide, cytarabine and melphalan in 84 patients and high-dose idarubicin and melphalan in 13 patients with subsequent peripheral hemopoietic stem cells transplant. Outcomes were evaluated in terms of progression-free survival (PFS) and overall survival (OS). In order to identify prognostic factors for outcome, a multivariate analysis for age, sex, disease status (refractory/relapsed), disease stage, B symptoms, presence of extranodal involvement, bulky disease, elevated lactate dehydrogenase, number of previous chemotherapy lines, remission status before transplant, 18F-fluoro-deoxy-d-glucose positron emission tomography (18FDG-PET) status before and after transplant was done. A clinical response was achieved in 91{\%} of patients, with complete remissions in 76/97 patients. With a median follow-up of 45months (range 1-164months), 5-year PFS and OS were 64{\%} and 71{\%}, respectively. Remission status after induction therapy, 18F-fluoro-deoxy-d-glucose positron emission tomography status before and after transplant were the most important prognostic factors for PFS and OS in univariate or multivariate analyses. HDCT is able to induce a high remission rate and a prolonged PFS in more than 50{\%} of the patients with refractory and relapsed HL.",
keywords = "Autologous transplant, High-dose chemotherapy, Hodgkin lymphoma",
author = "E. Cocorocchio and F. Peccatori and A. Vanazzi and G. Piperno and L. Calabrese and E. Botteri and L. Travaini and L. Preda and G. Martinelli",
year = "2013",
month = "3",
doi = "10.1002/hon.2014",
language = "English",
volume = "31",
pages = "34--40",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "1",

}

TY - JOUR

T1 - High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients

T2 - A reappraisal of prognostic factors

AU - Cocorocchio, E.

AU - Peccatori, F.

AU - Vanazzi, A.

AU - Piperno, G.

AU - Calabrese, L.

AU - Botteri, E.

AU - Travaini, L.

AU - Preda, L.

AU - Martinelli, G.

PY - 2013/3

Y1 - 2013/3

N2 - High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Treatment included high-dose carmustine, etoposide, cytarabine and melphalan in 84 patients and high-dose idarubicin and melphalan in 13 patients with subsequent peripheral hemopoietic stem cells transplant. Outcomes were evaluated in terms of progression-free survival (PFS) and overall survival (OS). In order to identify prognostic factors for outcome, a multivariate analysis for age, sex, disease status (refractory/relapsed), disease stage, B symptoms, presence of extranodal involvement, bulky disease, elevated lactate dehydrogenase, number of previous chemotherapy lines, remission status before transplant, 18F-fluoro-deoxy-d-glucose positron emission tomography (18FDG-PET) status before and after transplant was done. A clinical response was achieved in 91% of patients, with complete remissions in 76/97 patients. With a median follow-up of 45months (range 1-164months), 5-year PFS and OS were 64% and 71%, respectively. Remission status after induction therapy, 18F-fluoro-deoxy-d-glucose positron emission tomography status before and after transplant were the most important prognostic factors for PFS and OS in univariate or multivariate analyses. HDCT is able to induce a high remission rate and a prolonged PFS in more than 50% of the patients with refractory and relapsed HL.

AB - High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Treatment included high-dose carmustine, etoposide, cytarabine and melphalan in 84 patients and high-dose idarubicin and melphalan in 13 patients with subsequent peripheral hemopoietic stem cells transplant. Outcomes were evaluated in terms of progression-free survival (PFS) and overall survival (OS). In order to identify prognostic factors for outcome, a multivariate analysis for age, sex, disease status (refractory/relapsed), disease stage, B symptoms, presence of extranodal involvement, bulky disease, elevated lactate dehydrogenase, number of previous chemotherapy lines, remission status before transplant, 18F-fluoro-deoxy-d-glucose positron emission tomography (18FDG-PET) status before and after transplant was done. A clinical response was achieved in 91% of patients, with complete remissions in 76/97 patients. With a median follow-up of 45months (range 1-164months), 5-year PFS and OS were 64% and 71%, respectively. Remission status after induction therapy, 18F-fluoro-deoxy-d-glucose positron emission tomography status before and after transplant were the most important prognostic factors for PFS and OS in univariate or multivariate analyses. HDCT is able to induce a high remission rate and a prolonged PFS in more than 50% of the patients with refractory and relapsed HL.

KW - Autologous transplant

KW - High-dose chemotherapy

KW - Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84874937439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874937439&partnerID=8YFLogxK

U2 - 10.1002/hon.2014

DO - 10.1002/hon.2014

M3 - Article

VL - 31

SP - 34

EP - 40

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 1

ER -